Next Article in Journal
A Review of Topical Diclofenac Use in Musculoskeletal Disease
Next Article in Special Issue
The Role of Monoclonal Antibodies in the Management of Leukemia
Previous Article in Journal
Cannabinoids and Viral Infections
Previous Article in Special Issue
Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE)
This is a comment on Pharmaceuticals 2010, 3(1), 146-157 .

Pharmaceuticals 2010, 3(6), 1887-1891; doi:10.3390/ph3061887
Commentary

In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157)

1,2,* , 2
 and 1,3
1 Meridian Biopharmaceuticals GmbH, Brunnerstrasse 59, 1230 Wien, Austria 2 Vela Pharmazeutische Entwicklung und Laboranalytik GmbH, Brunnerstrasse 59, 1230 Wien, Austria 3 Virologik GmbH, Henkestrasse 91, 91052 Erlangen, Germany
* Author to whom correspondence should be addressed.
Received: 29 April 2010 / Revised: 31 May 2010 / Accepted: 9 June 2010 / Published: 10 June 2010
(This article belongs to the Special Issue Monoclonal Antibody)
View Full-Text   |   Download PDF [146 KB, uploaded 10 June 2010]   |   Browse Figure

Abstract

To complete the review article by Abes and colleagues (Pharmaceuticals 2010, 3, 146–157) which provides a good overview on recently developed approaches for generation of glyco-modified antibodies and the impact of glyco-modification of antibodies on their effector functions, important information should be added, namely that — besides the Glycart and the Biowa approach to generate de-fucosylated antibodies — innovative, moss derived methods have been shown to generate glyco-modified antibodies with improved effector function profile.
Keywords: therapeutic antibodies; glyco-modified IgG; ADCC; CDC; Fc -γRIII therapeutic antibodies; glyco-modified IgG; ADCC; CDC; Fc -γRIII
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Nechansky, A.; Koller, I.; Kircheis, R. In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157). Pharmaceuticals 2010, 3, 1887-1891.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert